FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. has received clearance from the US FDA for its Investigational New Drug application for a clinical trial of narmafotinib in pancreatic cancer patients. The trial will investigate the combination of narmafotinib with the chemotherapy regimen FOLFIRINOX, which is commonly used in the US. This clearance marks a significant advancement for Amplia as it expands the clinical opportunities for narmafotinib.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Amplia Reports First Patient Dosing In Phase 2a Accent Trial
- Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
- Appendix 4D and Financial Report Half Year ended 30 Sep 23
- Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
- Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million
Later from Amplia Therapeutics
- Update on ACCENT Trial in Pancreatic Cancer
- Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
- Rights Issue Investor Slide Deck
- $4.27m Offer Successfully Completed and ACCENT Trial Update
- Preliminary Final Report and Annual Report YE 31 March 2024
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics